In conclusion, while AKT remains a biologically significant molecule with clear mechanistic links to PAX3-FOXO1-driven oncogenesis, the path toward its clinical targeting in ARMS is fraught with uncertainty. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.